estim withdraw guidanc
open pre-releas revenu year/
year consensu recent initi
estim compani also withdrew prior guidanc said
expect reduct sale next sever month reiter
valu converg amaz trial compani expens reduct effort
includ execut base pay reduct six month longer
term continu see attract pure-play surgic afib ablat
signific growth opportun call option remain fundament
construct name report full result
number top-lin revenu pre-announc
estim consensu remind deliber gone
conserv initi estim prior launch consensu estim
essenc compani took hit due shutdown implement
march estim tweak reflect pre-announc
unknown know make-up open
segment vs mi segment vs atriclip shape us vs ou number
shape margin look like move ahead
state obviou hodgepodg shutdown effort across us
global led situat compani wit fundament
headwind take time dissip said compani like
edward lifesciences/cryolife/atricur etc much better shape
side curv believ given rel emerg natur procedur
converg appeal use epi endo approach persistent/perman
af reduc af burden least clinic make sens devil though
detail sure reimburs dynam same-day vs stage
hybrid approach need fine-tun eventu could build
uniqu long-term competit advantag
year price histori atricur
manufactur market
surgic solut atrial fibril
analyst certif import disclosur see disclosur
surgic af ablat continu year/year clip
atriclip main growth driver y/i clip
converg trial success
reimburs rate surgic af ablat remain steadi
atriclip continu key growth driver
surgic af ablat open mi continu y/i clip
converg data readout hr
converg trial result better expect
margin expans sg synergi occur earier expect
converg outcom sub-optim
coronarviru mitig
month price target deriv use multipl sale estim slight premium
aggreg med-tech univers trade expect sale pure play difficult treat therapeut segment
real competitor horizon henc believ deserv premium aggreg univers
reimburs surgic af ablat lucr well-establish howev reimburs hybrid surgic af ablat
establish singl code industri tackl converg result publish interest note
converg repres signific mileston compani histori determin larg extent growth trajectori move
current pandem creat widespread uncertainti outlook despit surgeri deferr guidelin rel
benign toward procedur admittedli wide variat procedur depend thing normal
statement oper
number mm except per share
sale
sg
